Introduction
Recently, we described in vitro [1] and in vivo [2] safety (in rats) of four-drug nerve block (multimodal perineural anesthesia-analgesia [MMPNA]) combinations involving bupivacaine (BPV [2] ), ropivacaine (RPV [1] ), or midazolam (MDZ [1, 2] ) with the following three preservative-free injectable drugs: clonidine, buprenorphine, and dexamethasone (hereafter abbreviated as CBD) [1, 2] . In addition, we reported 1) clinical analgesic duration benchmark data for patients having received nerve blocks with combined BPV-CBD [3] and MDZ-CBD [4] ) and 2) benchmark patient perineural safety data [5] . These reports encompassed the time period from July 2011 through December 2014, and our patient care quality improvement program continues as of this writing. The current report entails the technical issue of the four-drug block mixture at the bedside, and the theoretical microbiology-related risks of such mixtures.
Our research team recently gained prospective clinical trial research funding for the comparison of BPV-CBD against plain BPV in lower extremity nerve blocks. In the regulatory proceedings for this research funding, we were required by our institutional review board (IRB) to submit an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA). In serial communications with the FDA regarding the IND process, one of the directives was for our team to provide details how BPV-CBD would be compounded, including the provision of microbial and endotoxin data to support the sterility of the compounded product via perineural administration (personal communication from FDA, IND 127171 Full Clinical Hold correspondence, August 26, 2015).
The specific aim of this manuscript is to describe the experimental methods used and results obtained to support the sterility of BPV-CBD mixed at the bedside in the block room of our tertiary care Veterans Hospital. The submission of the results of this experiment for publication was approved by the Veterans Affairs Pittsburgh Healthcare System Institutional Review Board Section for Non-Human Subjects Research (MIRB ID#03262, June 9 and June 20, 2016).
Methods

Overview
The required evaluation of drug compound sterility occurred in two separate phases: endotoxin assessment and assessment for microbial growth. For both phases, the experimental condition was the presence or absence of nonsterile and sterile gloves at the time of mixing: 1) no gloves, 2) nonsterile nitrile gloves (Microflex Corp., Reno, NV, USA), and 3) sterile gloves (Biogel, Norcross, GA, USA).
All drug mixing occurred in our institution's block room, the heating/ventilation/air conditioning (HVAC) specifications entailing six to seven air exchanges per hour. This procedure room has three patient bays and two access doors that were routinely left open to foot and gurney traffic. The three patient bays used full-length curtains for patient privacy, and the block cart used for mixing was located behind a plastered wall no less than 18 feet (5.5 meters) from either door. In our routine clinical practice (since 2011) of BPV-CBD mixtures, all drugs were compounded at this block cart ( Figure  1A ) or a similar block cart 80 feet (24 meters) away (outside a glass-encased isolated patient bay used for infection control precaution patients) ( Figure 1B ). Neither block cart featured any specific HVAC engineering involving a vacuum hood (an ISO class 5 environment, as specified in USP 797).
The block cart surface was cleaned with a standard antiseptic wipe (Super Sani-Cloth, Professional Disposables International, Inc., Orangeburg, NY, USA), then the hands of the drug mixer (author BAW) were cleansed with Purell hand sanitizer (GOJO Industries, Akron, OH, USA).
Drug Mixing Protocol
The methods used for this mixing protocol were compliant with published recommendations, such as using aseptic technique, swabbing the drug container with alcohol, and wearing hat and mask during drug preparation into sterile syringes [6] . The nerve block mixtures performed for these experiments were not used for patient care. For drug preparation, the indicated quantities of injectable preservative-free bupivacaine (source vial of 30 mL of 5 mg/mL, Hospira, Lake Forest, IL, USA), buprenorphine (300 mcg/mL, 1 mL source vial, PAR Pharmaceutical, Woodcliff Lake, NJ, USA), and dexamethasone (10 mg/mL, 0.1 mL, 1 mL source vial, Fresenius Kabi, Warrendale, PA, USA) were withdrawn from single use containers and injected into an empty sterile syringe. A single dose syringe of injectable clonidine (25 mcg, in 0.25 mL from a source vial of 10 mL, Mylan Pharmaceuticals, Morgantown, WV, USA) was added to this syringe along with a sufficient quantity of preservative-free 0.9% sodium chloride (Hospira, 20 mL source vial) to provide a total volume of 20 mL ( Table 1) . As controls, we also prepared plain bupivacaine syringes: The required quantity of injectable preservative-free bupivacaine (10 mL of 5 mg/mL) was withdrawn from a single use container and injected into an empty syringe. A sufficient quantity of preservative-free 0.9% sodium chloride (10 mL) was then added to the syringe to provide a total volume of 20 mL. Author SMP witnessed and documented the preparation of all syringes.
Endotoxin Testing
We used the following methodology to address the issue of endotoxin parameters, en route to verifying the sterility of the drugs. The equipment we used for sample testing was the Endosafe device (Charles River Laboratories International [three useful websites describing the testing device are listed here: http://www.criver. com/files/pdfs/emd/endotoxin/endosafe_pts_and_regulatory_ requirements_fda_guide.aspx, http://www.criver.com/files/ pdfs/emd/endotoxin/qc_en_d_endosafe_pts_datasheet.aspx, http://www.criver.com/files/pdfs/emd/endotoxin/endosafepts-and-regulatory-requirements.aspx]). This is an FDAapproved limulus amoebocyte lysate (LAL) testing system that is compliant with USP 85 (United States Pharmacopeial Convention, Interim Revision Announcement, April 1, 2011) FDA requirements. Within three hours after the syringes were prepared in the described conditions, all aliquots were extracted from the syringes and processed through the Endosafe device (one aliquot at a time, approximately 15 minutes per aliquot), per manufacturer specifications. All syringes were prepared beginning at approximately 12:30 PM ET, and all Endosafe tests were complete by approximately 3:15 PM ET. Of note, in preliminary testing a few days prior, there were prompts from the Endosafe device regarding the need for further dilution than those given in our original 1:1 mixtures. After telephone consultation with Charles River Laboratories, we diluted the mixtures to 1:10 (with the device still prompting further dilution) and 1:100 (which ultimately gave all negative responses for this test). Figure 1 Photographs of nerve block procedure carts in our institution. A) Shows the nerve block cart located in the procedure room with three patient bays, with the bays separated by curtains. The camera is in the third of three procedural bays, and the other two procedural bays are on the left and right side of the photograph. The heating/ ventilation/air conditioning (HVAC) specifications of this procedure room entail six to seven air exchanges per hour. B) Shows the nerve block cart positioned in the hall (no specific HVAC specifications for air exchanges) outside two separate isolation rooms (each with 6-7 air exchanges per hour) where nerve blocks are performed. To date, all of our institution's nerve block mixtures have been prepared at one of these two carts.
Microbial Testing
In collaboration with the Pathology and Laboratory Medicine section of our institution, a standard procedure was established to ascertain microbial colony counts obtained from compounding procedures. These mixing proceedings occurred weeks after the aforementioned endotoxin experiments. Again, the BPV-CBD, plain, and saline control syringes were prepared aseptically by author BAW and witnessed by coauthor SMP as described above; there was no syringe dilution for this experiment. The syringes were all then delivered to the microbiology laboratory for processing. Aliquots of 100 ll volume were dispensed onto blood agar plates from each syringe. Aliquots were then evenly distributed across the surface of the plate using Lazy-L spreaders (Sigma-Aldrich, St. Louis, MO, USA). The plates were then incubated at 35 o C and examined for bacterial growth at 24, 48, and 72 hours, respectively. The plates were also incubated at 35 o C and examined for fungal growth at 24, 48, and 72 hours, respectively. After 72 hours, the plates were removed from the incubator and examined for fungal growth at five days, 10 days, and finalized at 14 days.
Statistical Analyses
All test results were negative, so no statistical analyses were required.
Results
Endotoxin Testing
There was no endotoxin detected in any samples of the 1:100 diluted syringes. The undiluted syringes and 1:10 diluted syringes were not interpretable by the device, likely (per phone consultation with the device manufacturer) related to exceeding osmolality limits.
Microbial Testing
There was no microbial (neither bacterial nor fungal) growth in any of the blood agar plates throughout the 14-day period.
After review of the results above, the FDA removed the Full Clinical Hold and concluded that the clinical trial may be initiated upon IRB approval. The FDA recommendation during the study was to ensure that the perineural administration of the four-drug nerve block (or plain bupivacaine control block) occurred within one hour of aseptic drug preparation in the syringe.
Discussion
We summarize the proceedings of our response to the Full Clinical Hold applied by the FDA on our IND application for the study of BPV-CBD as follows. Both endotoxin testing and microbial testing were negative for all samples, irrespective of the wearing of gloves or sterility of the gloves. It is noteworthy that we were required by the manufacturer of the endotoxin testing device to dilute the mixture to 1:100 to sufficiently minimize the solute concentration (of primarily local anesthetic) to allow for device interpretation of the injectate; obviously, such dilutions would also dilute endotoxin generated from the mixture, if such existed. The coinciding negative microbial testing offsets any concerns of the nuance of drug mixture dilution. Aside from the question of glove use, there were other aseptic preparation measures such as isopropyl alcohol hand rinse (e.g., Purell), the donning of a mask and hat, and aseptic decontamination wipes to the top surface and drawer fronts of our nerve block cart. This type of block cart arrangement (Figure 1 ) was the mixing location of our institutional standard of care four-drug nerve block mixtures since our program inception in 2011. The negative findings (verifying sterility) are supportive of both our current practice of drug preparation and the practice we aim to use for the prospective study. In our practice to date (over 3,000 patients with single-or dual-injection blocks), we have had no focal infectious concerns at the site of injection, to our knowledge. Our findings also support (related to any sterility concerns) the potential use of the four-drug combination by the study sponsor's (Department of Defense's) medical services in combat and/or other austere environments [7] .
These proceedings and our findings have potential patient benefits when considering interdisciplinary policy within a hospital. In our recent reports published in this journal [3, 5] , we described an associated analgesic duration from BPV-CBD exceeding a mean of 30 hours, with potential adjuvant dose response-driven improvements in rebound pain. Favorable durations such as this (with single-injection blocks) may reduce perineural catheter burden.
For a hospital that may have previously used perineural catheters, the multidrug combination as a single injection (initiated in an effort to replace a perineural catheter program) may generate procedural sterility questions. Such questions may specifically entail sterility of a multidrug combination for a single-injection nerve block prepared outside the confines of an ISO class 5 environment, that is, within a biological safety cabinet as noted within the standards of USP 797. For some facilities, the nerve block solutions are prepared in the operating room (15 air exchanges per hour) or a procedure room in close proximity to the operating room (e.g., 6-7 air exchanges per hour). In our facility, there are designated block carts in the latter-listed procedure rooms ( Figure 1 ) used for the preparation of nerve block solutions. Our standard practice for mixing nerve blocks on these carts includes hand sanitizing, decontamination of the block cart surface table, and using sterile syringes, needles, and single dose vials. These practices of our group were considered both sufficient and acceptable by the FDA and did not entail a formal declaration of sterile glove use (or any glove use, after the described hand cleansing) superimposed upon these other measures. In context, the risk of clinically relevant infectious complications from perineural catheters has been cited as 0-3% [8] .
Regarding the FDA's recommendation for our study that all drugs be administered within one hour of bedside preparation (despite being free from endotoxin and microbial growth), we reiterate from our team's recent publication in this journal [2] that the BPV-CBD mixture (in an ISO class 5 environment) is chemically compatible (without the precipitation of solute or loss of drug constitution) for at least 14 days after preparation. If such syringes were prepared within a hospital aseptically by pharmacists under the ISO class 5 conditions stated by USP 797 and refrigerated, then the block team would certainly have more flexibility regarding when to administer the block relative to the anticipated timing of surgery.
Conclusions
Some facilities do not have the benefit of access to ISO class 5 environments and/or a satellite pharmacy to prepare nerve block mixtures. At our facility, standard procedures for preparation were followed, including but not limited to donning hat and mask, hand sanitization, decontamination of the mixing surface, and using a sterile syringe and needle to access single dose vials. The negative results of our endotoxin and microbial growth assessments offer preliminary assurances regarding the sterility of a four-drug nerve block mixture prepared in the "Immediate Patient Treatment Area," that is, outside the confines of a biological safety cabinet and within the limited time frames previously described. These measures were deemed acceptable by the FDA in their approval of our IND application. We re-emphasize that the four-drug combination described, along with our mixing method, should otherwise be considered "off-label."
